Biosimilar Regulatory Roundup: September 2020
By: Skylar Jeremias of the Center for Biosimilars Despite the United States have a lower number of biosimilar approvals and launches throughout 2020, regulators have not slowed down in trying to expand biosimilar utilization as a way to lower costs and increase access to care for patients. New Legislation In early September, Representative Glenn Grothman,…
